866-997-4948 (US-Canada Toll Free)

Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries

Published By :

GBI Research

Published Date : 2014-01-16

Category :

Therapeutic Area

No. of Pages : 90

Product Synopsis


GBI Research, the leading business intelligence provider, has released its latest research, ‘Gastrointestinal Therapeutics (Irritable Bowel Syndrome, Ulcerative Colitis and Crohn’s Disease) in Major Developed Markets’, which provides insights into three gastrointestinal therapeutic indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of three gastrointestinal therapeutics markets, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn’s Disease (CD). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three gastrointestinal indications. 

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research’s team of industry experts. In 2012, the value of the gastrointestinal therapeutics market in major developed countries amounted to an estimated $6.8 billion. This total is forecast to decline at a Compound Annual Growth Rate (CAGR) of 0.3% between 2012 and 2019. The value of the IBS market amounted to an estimated $727m, and is forecast to increase at a CAGR of 14.4% between 2012 and 2019. The value of the UC market amounted to an estimated $2.2 billion in 2012, and is expected to increase at a CAGR of 6% during the forecast period. The value of the CD market amounted to an estimated $3.8 billion, which is expected to decline at a CAGR of 7.5% between 2012 and 2019.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals for the IBS, UC and CD indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada.

The report includes:

  • Disease overview and treatment usage patterns
  • Market size and forecast for IBS, UC and CD in major developed markets from 2012 to 2019
  • Major marketed products for the indication types covered
  • In-depth pipeline analysis for IBS, UC and CD
  • Key drivers and restraints that have had and are expected to have a major impact upon the market
  • Key licensing and co-development agreements in the gastrointestinal therapeutics market

Reasons to Buy

This report will enhance your decision-making capability by enabling you to:

  • Align your product portfolio to the markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments that are poised for strong growth
  • Devise a more effectively tailored country-specific strategy through the understanding of key drivers and barriers in the gastrointestinal therapeutics market
  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Table Of Content

Table of Content

1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 11

2 Gastrointestinal Therapeutics in Major Developed Markets – Introduction 12
2.1 Irritable Bowel Syndrome 12
2.1.1 Classification 12
2.1.2 Symptoms 12
2.1.3 Etiology 12
2.1.4 Pathophysiology 13
2.1.5 Diagnosis 13
2.1.6 Epidemiology 14
2.1.7 Prognosis 15
2.1.8 Treatment Options 15
2.2 Ulcerative Colitis 16
2.2.1 Classification 16
2.2.2 Symptoms 17
2.2.3 Etiology 17
2.2.4 Pathophysiology 18
2.2.5 Diagnosis 18
2.2.6 Epidemiology 19
2.2.7 Prognosis 19
2.2.8 Treatment Options 20
2.3 Crohn’s Disease 21
2.3.1 Classification 21
2.3.2 Symptoms 22
2.3.3 Etiology 22
2.3.4 Pathophysiology 23
2.3.5 Diagnosis 23
2.3.6 Epidemiology 24
2.3.7 Prognosis 24
2.3.8 Treatment Options 25

3 Gastrointestinal Therapeutics in Major Developed Markets – Marketed Products (Global) 26
3.1 Irritable Bowel Syndrome 26
3.2 Ulcerative Colitis 26
3.3 Crohn’s Disease 26
3.4 Key Marketed Products 27
3.4.1 Amitiza 27
3.4.2 Humira 28
3.4.3 Remicade 29
3.4.4 Simponi 30
3.4.5 Cimzia 31
3.4.6 Tysabri 32

4 Gastrointestinal Therapeutics in Major Developed Markets – Pipeline Analysis 34
4.1 Irritable Bowel Syndrome 34
4.1.1 Overall Pipeline 34
4.1.2 Pipeline Analysis by Molecule Type 36
4.1.3 Pipeline Analysis by Mechanism of Action 37
4.2 Ulcerative Colitis Pipeline 39
4.2.1 Overall Pipeline 39
4.2.2 Pipeline Analysis by Molecule Type 41
4.2.3 Pipeline Analysis by Mechanism of Action 42
4.3 Crohn’s Disease Pipeline 44
4.3.1 Overall Pipeline 44
4.3.2 Pipeline Analysis by Molecule Type 46
4.3.3 Pipeline Analysis by Mechanism of Action 47
4.4 Promising Drug Candidates in the Pipeline 49
4.4.1 GSK-1605786 49
4.4.2 MLN0002 49
4.4.3 EMD-61753 49

5 Gastrointestinal Therapeutics in Major Developed Markets – Market Forecast to 2019 50
5.1 Major Developed Markets 50
5.1.1 Treatment Usage Patterns 50
5.1.2 Annual Cost of Therapy 50
5.1.3 Market Size 50
5.2 US 52
5.2.1 Treatment Usage Patterns 52
5.2.2 Annual Cost of Therapy 52
5.2.3 Market Size 52
5.3 Europe 54
5.3.1 Treatment Usage Patterns 54
5.3.2 Annual Cost of Therapy 54
5.3.3 Market Size 54
5.4 Canada 56
5.4.1 Treatment Usage Patterns 56
5.4.2 Annual Cost of Therapy 56
5.4.3 Market Size 56
5.5 Japan 58
5.5.1 Treatment Usage Patterns 58
5.5.2 Annual Cost of Therapy 58
5.5.3 Market Size 58
5.6 Drivers and Barriers 60
5.6.1 Drivers 60
5.6.2 Barriers 60

6 Gastrointestinal Therapeutics in Major Developed Markets – Deals and Strategic Consolidations (Global) 62
6.1 Deals Analysis 62
6.2 Major Co-Development Deals 64
6.2.1 AstraZeneca Enters into Co-Development Agreement with Ironwood Pharma for Linaclotide 65
6.2.2 Amgen Enters into Co-development Agreement with AstraZeneca for Five Monoclonal Antibodies 65
6.2.3 Galapagos and AbbVie Extend GLPG0634 Development Agreement to Include Crohn's Disease 65
6.3 Major Licensing Deals 66
6.3.1 AstraZeneca Enters into Licensing Agreement with Ardelyx for NHE3 Inhibitor Program 67
6.3.2 Sanofi-Aventis Enters into Licensing Agreement with Kyowa Hakko Kirin 67
6.3.3 GlaxoSmithKline Enters into Licensing Agreement with ChemoCentryx 67

7 Gastrointestinal Therapeutics in Major Developed Markets – Appendix 68
7.1 All Pipeline Drugs by Phase 68
7.1.1 Discovery 68
7.1.2 Preclinical 68
7.1.3 IND/CTA-filed 69
7.1.4 Phase I 70
7.1.5 Phase II 71
7.1.6 Phase III 73
7.1.7 Pre-Registration 73
7.1.8 Undisclosed 74
7.2 Market Forecasts to 2019 74
7.2.1 Major Developed Markets 74
7.2.2 US 75
7.2.3 Canada 76
7.2.4 UK 77
7.2.5 France 78
7.2.6 Germany 79
7.2.7 Italy 80
7.2.8 Spain 81
7.2.9 Japan 82
7.3 Market Definitions 83
7.4 Abbreviations 83
7.5 Sources 85
7.6 Research Methodology 87
7.6.1 Coverage 87
7.6.2 Secondary Research 87
7.6.3 Primary Research 88
7.6.4 Therapeutic Landscape 88
7.6.5 Geographical Landscape 91
7.6.6 Pipeline Analysis 91
7.7 Expert Panel Validation 91
7.8 Contact Us 91
7.9 Disclaimer 91

List of Tables


Table 1: Gastrointestinal Therapeutics Market, Irritable Bowel Syndrome, Classification, 2009 12
Table 2: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Recommendations for Irritable Bowel Syndrome, 2009 16
Table 3: Gastrointestinal Therapeutics Market, Major Developed Markets, Classification of Ulcerative Colitis, 2004 16
Table 4: Gastrointestinal Therapeutics Market, Major Developed Markets, Diagnosis of Ulcerative Colitis, 2007 18
Table 5: Gastrointestinal Therapeutics Market, Major Developed Markets, Difference Between Ulcerative Colitis and Crohn’s Disease, 2007 19
Table 6: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Options of Ulcerative Colitis, 2011 21
Table 7: Gastrointestinal Therapeutics Market, Major Developed Markets, Classification of Crohn’s Disease, 2013 21
Table 8: Gastrointestinal Therapeutics Market, Major Developed Markets, Symptoms of Crohn’s Disease, 2012 22
Table 9: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Options for Crohn’s Disease , 2009 25
Table 10: Gastrointestinal Therapeutics Market, Global, Pipeline (Discovery), 2013 68
Table 11: Gastrointestinal Therapeutics Market, Global, Pipeline (Preclinical), 2013 68
Table 12: Gastrointestinal Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013 69
Table 13: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase I), 2013 70
Table 14: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase II), 2013 71
Table 15: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase III), 2013 73
Table 16: Gastrointestinal Therapeutics Market, Global, Pipeline (Pre-Registration), 2013 73
Table 17: Gastrointestinal Therapeutics Market, Global, Pipeline (Undisclosed), 2012 74
Table 18: Gastrointestinal Therapeutics Major Developed Markets, Irritable Bowel Syndrome, Market Forecast, 2012–2019 74
Table 19: Gastrointestinal Therapeutics Market, Major Developed Markets, Ulcerative Colitis, Market Forecast, 2012–2019 75
Table 20: Gastrointestinal Therapeutics Market, Major Developed Markets, Crohn’s Disease, Market Forecast, 2012–2019 75
Table 21: Gastrointestinal Therapeutics Market, US, Irritable Bowel Syndrome, Market Forecast, 2012–2019 75
Table 22: Gastrointestinal Therapeutics Market, US, Ulcerative Colitis, Market Forecast, 2012–2019 76
Table 23: Gastrointestinal Therapeutics Market, US, Crohn’s Disease, Market Forecast, 2012–2019 76
Table 24: Gastrointestinal Therapeutics Market, Canada, Irritable Bowel Syndrome, Market Forecast, 2012–2019 76
Table 25: Gastrointestinal Therapeutics Market, Canada, Ulcerative Colitis, Market Forecast, 2012–2019 77
Table 26: Gastrointestinal Therapeutics Market, Canada, Crohn’s Disease, Market Forecast, 2012–2019 77
Table 27: Gastrointestinal Therapeutics Market, UK, Irritable Bowel Syndrome, Market Forecast, 2012–2019 77
Table 28: Gastrointestinal Therapeutics Market, UK, Ulcerative Colitis, Market Forecast, 2012–2019 78
Table 29: Gastrointestinal Therapeutics Market, UK, Crohn’s Disease, Market Forecast, 2012–2019 78
Table 30: Gastrointestinal Therapeutics Market, France, Irritable Bowel Syndrome, Market Forecast, 2012–2019 78
Table 31: Gastrointestinal Therapeutics Market, France, Ulcerative Colitis, Market Forecast, 2012–2019 79
Table 32: Gastrointestinal Therapeutics Market, France, Crohn’s Disease, Market Forecast, 2012–2019 79
Table 33: Gastrointestinal Therapeutics Market, Germany, Irritable Bowel Syndrome, Market Forecast, 2012–2019 79
Table 34: Gastrointestinal Therapeutics Market, Germany, Ulcerative Colitis, Market Forecast, 2012–2019 80
Table 35: Gastrointestinal Therapeutics Market, Germany, Crohn’s Disease, Market Forecast, 2012–2019 80
Table 36: Gastrointestinal Therapeutics Market, Italy, Irritable Bowel Syndrome, Market Forecast, 2012–2019 80
Table 37: Gastrointestinal Therapeutics Market, Italy, Ulcerative Colitis, Market Forecast, 2012–2019 81
Table 38: Gastrointestinal Therapeutics Market, Italy, Crohn’s Disease, Market Forecast, 2012–2019 81
Table 39: Gastrointestinal Therapeutics Market, Spain, Irritable Bowel Syndrome, Market Forecast, 2012–2019 81
Table 40: Gastrointestinal Therapeutics Market, Spain, Ulcerative Colitis, Market Forecast, 2012–2019 82
Table 41: Gastrointestinal Therapeutics Market, Spain, Crohn’s Disease, Market Forecast, 2012–2019 82
Table 42: Gastrointestinal Therapeutics Market, Japan, Irritable Bowel Syndrome, Market Forecast, 2012–2019 82
Table 43: Gastrointestinal Therapeutics Market, Japan, Ulcerative Colitis, Market Forecast, 2012–2019 83
Table 44: Gastrointestinal Therapeutics Market, Japan, Crohn’s Disease, Market Forecast, 2012–2019 83

List of Figures


Figure 1: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Algorithm of Ulcerative Colitis, 2007 20
Figure 2: Gastrointestinal Therapeutics Market, Global, Sales of Amitiza ($m), 2006–2012 27
Figure 3: Gastrointestinal Therapeutics Market, Global, Sales of Humira ($bn), 2006–2012 28
Figure 4: Gastrointestinal Therapeutics Market, Global, Sales of Remicade ($bn), 2006–2012 29
Figure 5: Gastrointestinal Therapeutics Market, Global, Sales of Simponi ($m), 2009–2012 30
Figure 6: Gastrointestinal Therapeutics Market, Global, Sales of Cimzia ($m), 2008–2012 31
Figure 7: Gastrointestinal Therapeutics Market, Global, Sales of Tysabri ($m), 2006–2012 32
Figure 8: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline, 2013 35
Figure 9: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Molecule Type, 2013 36
Figure 10: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Mechanism of Action, 2012 38
Figure 11: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline, 2013 40
Figure 12: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Molecule Type, 2013 41
Figure 13: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Mechanism of Action, 2013 43
Figure 14: Gastrointestinal Therapeutics Market, Global, Crohn’s Disease, Pipeline, 2013 45
Figure 15: Gastrointestinal Therapeutics Market, Global, Crohn’s Disease, Pipeline by Molecule Type, 2013 46
Figure 16: Gastrointestinal Therapeutics Market, Global, Crohn’s Disease, Pipeline by Mechanism of Action, 2013 48
Figure 17: Gastrointestinal Therapeutics Market, Major Developed Markets, Market Size ($bn), 2012–2019 51
Figure 18: Gastrointestinal Therapeutics Market, US, Market Size ($bn), 2012–2019 53
Figure 19: Gastrointestinal Therapeutics Market, Top Five European Countries, Market Size ($bn), 2012–2019 55
Figure 20: Gastrointestinal Therapeutics Market, Canada, Market Size ($m), 2012–2019 57
Figure 21: Gastrointestinal Therapeutics Market, Japan, Market Size ($m), 2012–2019 59
Figure 22: Gastrointestinal Therapeutics Market, Global, Deals, 2006–2013 63
Figure 23: Gastrointestinal Therapeutics Market, Global, Co-Development Deals, 2006–2013 64
Figure 24: Gastrointestinal Therapeutics Market, Global, Licensing Deals, 2006–2013 66
Figure 25: GBI Research Market Forecasting Model 90

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Customer Relationship Management (CRM) Outsourcing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2014 - 2020

    By - Transparency

    Outsourcing is a process where an organization selects an efficient third party service provider to effectively manage and operate its customer relationship management unit. Outsourcing of the CRM activities has emerged as a promising solution to meet increasing demand for quality CRM activities and rising costs associated with it. The CRM industry is in the process of revolutionizing itself with the addition of new services offerings such as modern communication and social media platforms. In addition, the CRM activities, which provide flexibility for both clients and workers, are...

  • Wireless Backhaul Via Satellite Market - Global Industry Analysis, Market Size, Share, Growth, Trends And Forecast, 2013 - 2019

    By - Transparency

    Satellite backhaul for wireless and cellular services is being used to expand network coverage over remote and difficult locations. Backhaul via satellite also finds application in emergency communications, backup networks, off-loading cellular traffic and temporary solution in region where cell-towers have not been deployed. The demand for wireless backhaul via satellite is driven by the universal need to stay connected. Further, satellite backhauls are often cheaper than microwave or fiber networks in remote geographical locations. Although, the 2G, 3G, and LTE network coverage continues...

  • Tantalum Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

    By - Transparency

    Tantalum is a hard, bluish grey, transition metal. Previously it was known as tantalium and is a rare earth metal. It is characterized by its incredibly high melting point which is bettered only by tungsten, rhenium, osmium and carbon. Tantalum along with similar metals such as Neobium, can be found in minerals such as coltan, columbite and tantalite. Most of the tantalum is derived from hard rock mines; however it can also be obtained from tin slags, and artisanal mines. Tantalite is highly resistant to corrosion and is a part of the refractory metals group.  The main...